These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 1547685

  • 1. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
    Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF.
    Diabetes Care; 1992 Feb; 15(2):270-6. PubMed ID: 1547685
    [Abstract] [Full Text] [Related]

  • 2. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB, Madsbad S, Holst JJ.
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [Abstract] [Full Text] [Related]

  • 3. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.
    Egan JM, Clocquet AR, Elahi D.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1282-90. PubMed ID: 11889200
    [Abstract] [Full Text] [Related]

  • 4. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 5. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 6. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [Abstract] [Full Text] [Related]

  • 7. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K.
    Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
    [Abstract] [Full Text] [Related]

  • 8. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
    Lugari R, Dell'Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R, Marani B, Iotti M, Orlandini A, Gnudi A.
    Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
    [Abstract] [Full Text] [Related]

  • 9. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 10. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
    Ryan AS, Egan JM, Habener JF, Elahi D.
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
    Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D.
    J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
    [Abstract] [Full Text] [Related]

  • 14. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
    Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA.
    Diabetes; 2000 Apr; 49(4):611-7. PubMed ID: 10871199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.
    Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [Abstract] [Full Text] [Related]

  • 19. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.